[{"address1": "2625 Townsgate Road", "address2": "Suite 230", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "805 267 9889", "website": "https://www.genelux.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Zindrick J.D.", "age": 63, "title": "Chairman, CEO & President", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 570990, "exercisedValue": 0, "unexercisedValue": 11528577}, {"maxAge": 1, "name": "Ms. Lourie S. Zak", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 346195, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Jewett", "age": 58, "title": "VP & Head of Quality", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 269264, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph  Cappello Ph.D.", "age": 66, "title": "Chief Technical Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 213077, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  Ryder J.D.", "age": 53, "title": "General Counsel & Corporate Secretary", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 380000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yong  Yu Ph.D.", "age": 51, "title": "Senior Vice President of Clinical Development", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 242615, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Paul  Scigalla M.D., Ph.D.", "age": 77, "title": "Chief Medical Officer", "yearBorn": 1946, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ralph  Smalling B.Sc.", "age": 66, "title": "VP & Head of Regulatory Affairs", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.45, "open": 3.5, "dayLow": 3.08, "dayHigh": 3.398, "regularMarketPreviousClose": 3.45, "regularMarketOpen": 3.5, "regularMarketDayLow": 3.08, "regularMarketDayHigh": 3.398, "forwardPE": -2.8869565, "volume": 147726, "regularMarketVolume": 147726, "averageVolume": 140572, "averageVolume10days": 160630, "averageDailyVolume10Day": 160630, "bid": 3.29, "ask": 3.37, "bidSize": 400, "askSize": 100, "marketCap": 89193456, "fiftyTwoWeekLow": 3.07, "fiftyTwoWeekHigh": 40.98, "priceToSalesTrailing12Months": 524.66736, "fiftyDayAverage": 5.8005, "twoHundredDayAverage": 15.1499, "currency": "USD", "enterpriseValue": 67082704, "floatShares": 19944107, "sharesOutstanding": 26865500, "sharesShort": 2034212, "sharesShortPriorMonth": 1845318, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0757, "heldPercentInsiders": 0.22309, "heldPercentInstitutions": 0.21774, "shortRatio": 19.05, "shortPercentOfFloat": 0.0943, "impliedSharesOutstanding": 26865500, "bookValue": 0.739, "priceToBook": 4.492557, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -28297000, "trailingEps": -1.16, "forwardEps": -1.15, "enterpriseToRevenue": 394.604, "enterpriseToEbitda": -2.835, "52WeekChange": -0.8627532, "SandP52WeekChange": 0.21080327, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GNLX", "underlyingSymbol": "GNLX", "shortName": "Genelux Corporation", "longName": "Genelux Corporation", "firstTradeDateEpochUtc": 1674743400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "818a2610-5027-31af-b56b-57304f2478db", "messageBoardId": "finmb_11172383", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.32, "targetHighPrice": 32.0, "targetLowPrice": 18.0, "targetMeanPrice": 26.0, "targetMedianPrice": 27.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 23191000, "totalCashPerShare": 0.877, "ebitda": -23666000, "totalDebt": 2519000, "quickRatio": 3.538, "currentRatio": 3.693, "totalRevenue": 170000, "debtToEquity": 12.936, "revenuePerShare": 0.007, "returnOnAssets": -0.90373003, "freeCashflow": -19375876, "operatingCashflow": -20275000, "revenueGrowth": -1.0, "grossMargins": 1.0, "operatingMargins": -142.14706, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]